- 05 lug.- 09:06

AGIC Capital Completes Investment into Eulitha AG

Business Wire.
  • AGIC Capital invests into Switzerland-based Eulitha, a leading provider of non-contact Nano-UV-Lithography equipment and services
  • AGIC Capital will work with the management team to accelerate Eulitha’s growth globally and promote its proprietary PHABLE™ technology solution for the AR/VR, advanced optical components, and other industries


- 05 lug.- 09:00

POST Luxembourg uses ADVA’s optical cesium atomic clock to combat GNSS attacks and improve PNT resilience

Business Wire.

News summary:

  • Leading service provider needed highly efficient way to achieve ultra-stable and resilient synchronization
  • ADVA’s OSA 3350 ePRC+ solution delivers assured PNT GNSS backup with new levels of accuracy and availability
  • Industry-first high-precision optical cesium device offers unrivaled holdover and double the lifetime of legacy magnetic cesium clocks
- 04 lug.- 09:58

BearingPoint Appoints 19 New Partners Across Europe

Business Wire.

The management and technology consultancy continues to strengthen its position as an independent European firm, and the new appointments underline its growth and Strategy 2025 ambitions

- 01 lug.- 13:00

NielsenIQ e GfK si uniscono per diventare il principale fornitore globale di informazioni e analisi del settore retail e dei consumatori

Business Wire.
  • L'unione di due leader globali, che forniscono servizi ai principali produttori e distributori, permetterà di completare l'offerta in ambito retail e consumer attraverso tecnologie all'avanguardia.
  • L’unione darà vita a una società leader nella fornitura di dati e nella misurazione retail e consumer, rafforzandone la copertura omnichannel.
  • La nuova società avrà un'impronta globale e una copertura del settore senza precedenti: fornirà soluzioni innovative ai clienti, assicurando nuove prospettive di crescita.
  • Advent International (“Advent”) sarà l'azionista di maggioranza della nuova società, mentre il Nuremberg Institute for Market Decisions (“NIM”) e KKR rimarranno importanti azionisti.
- 30 giu.- 00:01

Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years

Business Wire.
  • Children Ages 2 to <12 Experienced 94.8% Fewer Hereditary Angioedema (HAE) Attacks During Treatment with TAKHZYRO Over the 52-Week Treatment Period Compared to Baseline
  • Late-Breaking Flash Talk Presentation of Phase 3 Data Highlights Positive, Clinically Meaningful Results in Children <6 Years, Where No Long-Term Prophylaxis Treatment (LTP) is Currently Approved
  • Results are Consistent with the Favorable Efficacy and Safety Profile of TAKHZYRO Observed in Adult and Adolescent Patients in Earlier Studies
  • Global Regulatory Filings to Begin in Fiscal Year 2022

Video Economia


ANSAVoice EconoMIA

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni

Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA
Vai alla rubrica: Poste News
Vai alla rubrica: Pianeta Camere
Vai alla rubrica: Agrimercati
Vai alla rubrica: PMI

Real Estate

Criptovalute news

Modifica consenso Cookie